Jerry Vockley, MD, PhD
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jerry Vockley, MD, PhD sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Jerry Vockley, MD, PhD: 2 sponsored US clinical trials, 2 recruiting.
Jerry Vockley, MD, PhD sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Medium-chain Acyl-CoA Dehydrogenase Deficiency, with 2 trials.
Mid-pack sponsor footprint
Jerry Vockley, MD, PhD is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
NCT07097311
Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
NCT06773026
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Jerry Vockley, MD, PhD pipeline
2 recruiting of 2 indexed (100% open).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Medium-chain Acyl-CoA Dehydrogenase Deficiency (2 trials), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jerry Vockley, MD, PhD: open-pipeline peers nationwide
Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Jerry Vockley, MD, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Jerry Vockley, MD, PhD page
2 registered trials is a research-attention snapshot, not an endorsement of Jerry Vockley, MD, PhD or any single study.
- 2 of Jerry Vockley, MD, PhD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Medium-chain Acyl-CoA Dehydrogenase Deficiency is the condition Jerry Vockley, MD, PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Medium-chain Acyl-CoA Dehydrogenase Deficiency trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jerry Vockley, MD, PhD pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.